263 related articles for article (PubMed ID: 30472601)
21. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.
Minami J; Suzuki R; Mazitschek R; Gorgun G; Ghosh B; Cirstea D; Hu Y; Mimura N; Ohguchi H; Cottini F; Jakubikova J; Munshi NC; Haggarty SJ; Richardson PG; Hideshima T; Anderson KC
Leukemia; 2014 Mar; 28(3):680-9. PubMed ID: 23913134
[TBL] [Abstract][Full Text] [Related]
22. Perspectives and new aspects of histone deacetylase inhibitors in the therapy of CNS diseases.
Han B; Wang M; Li J; Chen Q; Sun N; Yang X; Zhang Q
Eur J Med Chem; 2023 Oct; 258():115613. PubMed ID: 37399711
[TBL] [Abstract][Full Text] [Related]
23. Emerging approaches for histone deacetylase inhibitor drug discovery.
Zwergel C; Valente S; Jacob C; Mai A
Expert Opin Drug Discov; 2015 Jun; 10(6):599-613. PubMed ID: 25895649
[TBL] [Abstract][Full Text] [Related]
24. HDAC Inhibitors--CHI's Third Annual Conference.
Rosato RR
IDrugs; 2010 Jan; 13(1):13-5. PubMed ID: 20024840
[TBL] [Abstract][Full Text] [Related]
25. The role of histone deacetylase 3 in breast cancer.
Rahbari R; Rasmi Y; Khadem-Ansari MH; Abdi M
Med Oncol; 2022 May; 39(5):84. PubMed ID: 35578147
[TBL] [Abstract][Full Text] [Related]
26. An overview of naturally occurring histone deacetylase inhibitors.
Kim B; Hong J
Curr Top Med Chem; 2015; 14(24):2759-82. PubMed ID: 25487010
[TBL] [Abstract][Full Text] [Related]
27. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
McLeod AB; Stice JP; Wardell SE; Alley HM; Chang CY; McDonnell DP
Prostate; 2018 Mar; 78(4):266-277. PubMed ID: 29243324
[TBL] [Abstract][Full Text] [Related]
28. A novel class of anthraquinone-based HDAC6 inhibitors.
Song Y; Lim J; Seo YH
Eur J Med Chem; 2019 Feb; 164():263-272. PubMed ID: 30597327
[TBL] [Abstract][Full Text] [Related]
29. [Role of HDAC isoforms and development of treatment of multiple myeloma using isoform-specific HDAC inhibitors].
Harada T
Rinsho Ketsueki; 2019; 60(9):1265-1274. PubMed ID: 31597852
[TBL] [Abstract][Full Text] [Related]
30. Human neuronal cells: epigenetic aspects.
Kukucka J; Wyllie T; Read J; Mahoney L; Suphioglu C
Biomol Concepts; 2013 Aug; 4(4):319-33. PubMed ID: 25436583
[TBL] [Abstract][Full Text] [Related]
31. Development and therapeutic impact of HDAC6-selective inhibitors.
Dallavalle S; Pisano C; Zunino F
Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
[TBL] [Abstract][Full Text] [Related]
32. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
Noureen N; Rashid H; Kalsoom S
Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
[TBL] [Abstract][Full Text] [Related]
33. Novel histone deacetylase 6 (HDAC6) selective inhibitors: a patent evaluation (WO2014181137).
Simões-Pires CA; Bertrand P; Cuendet M
Expert Opin Ther Pat; 2017 Mar; 27(3):229-236. PubMed ID: 28092474
[TBL] [Abstract][Full Text] [Related]
34. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).
Methot JL; Chakravarty PK; Chenard M; Close J; Cruz JC; Dahlberg WK; Fleming J; Hamblett CL; Hamill JE; Harrington P; Harsch A; Heidebrecht R; Hughes B; Jung J; Kenific CM; Kral AM; Meinke PT; Middleton RE; Ozerova N; Sloman DL; Stanton MG; Szewczak AA; Tyagarajan S; Witter DJ; Secrist JP; Miller TA
Bioorg Med Chem Lett; 2008 Feb; 18(3):973-8. PubMed ID: 18182289
[TBL] [Abstract][Full Text] [Related]
35. Histone deacetylase 3 inhibitors in learning and memory processes with special emphasis on benzamides.
Amin SA; Adhikari N; Kotagiri S; Jha T; Ghosh B
Eur J Med Chem; 2019 Mar; 166():369-380. PubMed ID: 30735902
[TBL] [Abstract][Full Text] [Related]
36. Development and therapeutic implications of selective histone deacetylase 6 inhibitors.
Kalin JH; Bergman JA
J Med Chem; 2013 Aug; 56(16):6297-313. PubMed ID: 23627282
[TBL] [Abstract][Full Text] [Related]
37. HDAC3 inhibitors: a patent review of their broad-spectrum applications as therapeutic agents.
Makgoba TB; Kapp E; Egieyeh S; Joubert J
Expert Opin Ther Pat; 2024 Apr; 34(4):273-295. PubMed ID: 38873766
[TBL] [Abstract][Full Text] [Related]
38. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.
Gryder BE; Sodji QH; Oyelere AK
Future Med Chem; 2012 Mar; 4(4):505-24. PubMed ID: 22416777
[TBL] [Abstract][Full Text] [Related]
39. Natural products as zinc-dependent histone deacetylase inhibitors.
Tan S; Liu ZP
ChemMedChem; 2015 Mar; 10(3):441-50. PubMed ID: 25581683
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and biological screening of 2-aminobenzamides as selective HDAC3 inhibitors with promising anticancer effects.
Trivedi P; Adhikari N; Amin SA; Jha T; Ghosh B
Eur J Pharm Sci; 2018 Nov; 124():165-181. PubMed ID: 30171982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
